Earnings Feed
Start Free
Home/Filings/4/0001209191-14-060582
4//SEC Filing

VERTEX PHARMACEUTICALS INC / MA 4

Accession 0001209191-14-060582

$VRTXCIK 0000875320operating
View on SEC.govCompany Profile

Filed

Sep 30, 8:00 PM ET

Accepted

Oct 1, 5:08 PM ET

Size

26.4 KB

Accession

0001209191-14-060582

Insider Transaction Report

Form 4
Period: 2014-09-30
VERTEX PHARMACEUTICALS INC / MAVRTX
Connolly Thomas
SVP, Human Resources
Transactions
  • Exercise/Conversion

    Common Stock

    2014-09-30$83.36/sh+1,500$125,040→ 21,972 total
  • Exercise/Conversion

    Common Stock

    2014-09-30$77.31/sh+7,844$606,420→ 29,816 total
  • Sale

    Common Stock

    2014-09-30$111.29/sh−1,800$200,322→ 28,016 total
  • Sale

    Common Stock

    2014-09-30$112.18/sh−5,300$594,554→ 22,716 total
  • Sale

    Common Stock

    2014-09-30$113.03/sh−4,071$460,145→ 18,645 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2014-09-30−1,875→ 9,375 total
    Exercise: $45.11Exp: 2023-02-04→ Common Stock (1,875 underlying)
  • Exercise/Conversion

    Common Stock

    2014-09-30$53.74/sh+2,813$151,171→ 18,597 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2014-09-30−1,500→ 4,500 total
    Exercise: $83.36Exp: 2023-07-29→ Common Stock (1,500 underlying)
  • Sale

    Common Stock

    2014-09-30$113.89/sh−3,000$341,670→ 15,645 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2014-09-30−2,813→ 7,500 total
    Exercise: $53.74Exp: 2022-09-03→ Common Stock (2,813 underlying)
  • Exercise/Conversion

    Common Stock

    2014-09-30$45.11/sh+1,875$84,581→ 20,472 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2014-09-30−7,844→ 54,906 total
    Exercise: $77.31Exp: 2024-02-04→ Common Stock (7,844 underlying)
Holdings

  • Common Stock

    (indirect: By 401(k))
    150
Footnotes (10)
  • [F1]Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.
  • [F10]The option vests in 16 quarterly installments from 02/05/2014.
  • [F2]Open market sales reported on this line occurred at a weighted average price of $111.29 (range $110.61 to $111.58).
  • [F3]Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  • [F4]Open market sales reported on this line occurred at a weighted average price of $112.18 (range $111.61 to $112.60).
  • [F5]Open market sales reported on this line occurred at a weighted average price of $113.03 (range $112.61 to $113.59).
  • [F6]Open market sales reported on this line occurred at a weighted average price of $113.89 (range $113.61 to $114.31).
  • [F7]The option vests in 16 quarterly installments from 09/04/2012.
  • [F8]The option vests in 16 quarterly installments from 02/05/2013.
  • [F9]The option vests in 16 quarterly installments from 07/30/2013.

Documents

1 file

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

→
Entity typeoperating
IncorporatedMA

Related Parties

1
  • filerCIK 0000875320

Filing Metadata

Form type
4
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:08 PM ET
Size
26.4 KB
View on SEC.gov